Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Topamax(R) Tablets
Date:4/2/2009

DETROIT, April 2 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE AMEX: CPD) has launched Topiramate tablets on behalf of Sun Pharmaceutical Industries Ltd. (Sun Pharma), immediately following Sun Pharma's recently received approval from the US Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for generic Topamax(R) tablets.

Topiramate tablets are used as initial monotherapy in patients 10 years of age and older with partial onset seizures, or primary generalized tonic-clonic seizures. Topiramate tablets are indicated as adjunctive therapy for adults and pediatric patients ages 2-16 years with partial onset seizures, or primary generalized tonic-clonic seizures, and in patients 2 years of age and older with seizures associated with Lennox-Gastaut syndrome. These generic versions of Topamax 25 mg, 50 mg, 100 mg, and 200 mg tablets are bioequivalent to Topamax(R) which is a registered trademark of Ortho McNeil Janssen Pharmaceuticals, Inc. According to IMS Data, these strengths of Topiramate had US sales of approximately $2.3 billion for the calendar year of 2008.

Daniel H. Movens, Caraco's Chief Executive Officer, said, "We are pleased to add this product to our portfolio by launching Topiramate tablets immediately to the marketplace. We continue to focus on working towards expanding our product offering both as a marketing partner and through our own development pipeline of products as quickly and effectively as possible."

Detroit-based Caraco Pharmaceutical Laboratories, Ltd., develops, manufactures, markets and distributes generic and private-label pharmaceuticals to the nation's largest wholesalers, distributors, drugstore chains and managed care providers.

Safe Harbor: This news release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties are contained in the Corporation's filings with the Securities and Exchange Commission and include, but are not limited to: information of a preliminary nature that may be subject to adjustment, potentially not obtaining or delay in obtaining FDA approval for new products, governmental restrictions on the sale of certain products, development by competitors of new or superior products or cheaper products or new technology for the production of products, the entry into the market of new competitors, market and customer acceptance and demand for new pharmaceutical products, availability of raw materials, timing and success of product development and launches, dependence on few products generating majority of sales, product liability claims for which the Company may be inadequately insured, and other risks identified in this report and from time to time in our periodic reports and registration statements. These forward-looking statements represent our judgment as of the date of this report. We disclaim, however, any intent or obligation to update our forward-looking statements.


'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces a Nationwide Voluntary Recall of All Lots of Digoxin Tablets Due to Size Variability
2. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal 2009
3. Caraco Pharmaceutical Laboratories, Ltd. to Announce Third Quarter of Fiscal Year 2009 Results on January 29, 2009
4. Caraco Pharmaceutical Laboratories, Ltd. Responds to FDA Warning Letter
5. Caraco Pharmaceutical Laboratories, Ltd. Update on FDA Warning Letter
6. Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Sinemet(R) Tablets
7. Caraco Pharmaceutical Laboratories, Ltd. Reaches Agreement with Labor Union
8. Caraco Pharmaceutical Laboratories, Ltd. to Market Generic Depakote(R) Delayed Release Tablets
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Elavil(R)
10. Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008
11. Caraco Pharmaceutical Laboratories, Ltd. to Announce Fourth Quarter and Fiscal Year 2008 Results on May 29, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... (PRWEB) , ... November 30, 2016 , ... ... to announce that we have been designated as a Cigna Infertility Center of ... exceed rigorous performance standards. , “It’s an honor to be designated a ...
(Date:11/30/2016)... ... ... "I hate when the mixture of saliva and toothpaste runs down my toothbrush ... N.J. "I thought that there had to be a way to prevent this mess, ... to prevent saliva and toothpaste from running down the brush handle onto the hand ...
(Date:11/30/2016)... ... November 30, 2016 , ... Center For Discovery, a ... opening of a new eating disorder treatment center location in Palm Beach Gardens, ... and adolescents, both males and females ages 10 and older with eating disorders, ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... workers have been a focus of public policymakers and system stakeholders in many ... (WCRI) released its Medical Price Index for Workers’ Compensation, Eighth Edition (MPI-WC) ...
(Date:11/30/2016)... ... November 30, 2016 , ... The ... community that the FDA Binding Guidance goes into effect next month. Sponsors whose ... in the FDA Data Standards Catalog. The current FDA Data Standards Catalog specifies ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... bioLytical Laboratories (das "Unternehmen"), ein Weltführer bei schnellen Tests für ... einer Version mit geringeren Kosten einzuführen.  Continue ... ... INSTI Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444833 ) Der von ...
(Date:12/2/2016)... , December 2, 2016 ... its past losses following Trump,s victory early in November. ... and fund managers are now predicting an uptick in ... four equities to see how they have fared at ... CLDX ), Amicus Therapeutics Inc. (NASDAQ: FOLD ...
(Date:11/30/2016)... DUBLIN , Nov 30, 2016 ... "US Market Overview for Neuromodulation, Neurovascular, Neurosurgical and Monitoring ... ... The full report suite on ... cerebrospinal fluid external drainage systems, intracranial pressure monitoring devices, detachable ...
Breaking Medicine Technology: